A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Paliperidone (Primary) ; Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 18 Nov 2019 Planned End Date changed from 19 May 2020 to 6 Dec 2019.
- 18 Nov 2019 Planned primary completion date changed from 10 Apr 2020 to 6 Dec 2019.
- 18 Nov 2019 Status changed from recruiting to active, no longer recruiting.